A drug discovery company dedicated to developing treatments for Neurofibromatosis Type 1

Grant & Funding Partners

iNFixion Bioscience is currently seeking scientific collaboration and investment opportunities. Please reach out anytime to Herb Sarnoff (CEO) at herb@infixionbio.com to schedule an initial meeting.


Infixion updates

Company Newsletters

Infixion updates

Latest News

The University of Wisconsin Biotechnology Center (UWBC) and iNFixion Bioscience have launched a multi-year collaboration to execute assay development and library screening focused on identifying small molecule NF1 transcriptional regulators.

iNFixion Bioscience announced ongoing collaborations with individual researchers from the University of Arizona, the University of Alabama Huntsville, and the Broad Institute in order to build tools to study NF1 haploinsufficiency.  These projects include developing machine learning models to identify compounds impacting NF1 gene expression and the development of synthetic transcription factors to specifically increase NF1 protein expression during in vitro experimentation.  These efforts are being supported in part by grants from NF Northeast and NF North Central, both regional members of NF Network, a national organization advocating for and supporting individuals and families impacted by Neurofibromatosis.